Lifecore Biomedical, Inc.
NASDAQ:LFCR · NASDAQ Global Select
+$0.02 today
Vol 0.22M · Avg 0.29M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
0.0%
avg -54.0%
ROIC
0.0%
avg -2.7%
ROA
0.0%
avg -9.1%
Analysis
ROE is currently the strongest return metric at 0.0% versus its period average of -54.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Paul Josephs | President, Chief Executive Officer & Director | $782,079.00 | — | 60 | $69,967.00 | 0.19% |
Ryan D. Lake | Executive Vice President & Chief Financial Officer | $604,940.00 | — | 49 | $246,333.00 | 0.66% |
Thomas Salus | Chief Legal and Administration Officer & Corporate Secretary | $573,284.00 | — | 56 | $246,333.00 | 0.66% |
Parker K. Javid | Vice President | $321,908.00 | — | 57 | — | — |
Jackie Q. Klecker | Executive Vice President of Quality & Development Services | — | — | — | — | — |
Aaron Perlitsh | Director of Internal Audit & Chief Compliance Officer | — | — | — | — | — |
Thomas Guldager | Senior Vice President of Operations | — | — | — | $246,333.00 | 0.66% |
Mark DaFonseca | Chief Commercial Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +0.7% | N/A1 analysts |
| Revenue | N/A | N/A | +19.3% | -7.0% (15yr)2 analysts |
| Net Income | N/A | N/A | +2.2% | N/A2 analysts |
| EBIT | N/A | N/A | +8.2% | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +19.3% over three years. Forward estimates point to Revenue at -7.0% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
BioAge Labs, Inc.
NASDAQ:BIOA
$778.22M
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$504.06M
Canopy Growth Corporation
NASDAQ:CGC
$405.86M
Sight Sciences, Inc.
NASDAQ:SGHT
$280.21M
Alpha Teknova, Inc.
NASDAQ:TKNO
$276.92M
Owens & Minor, Inc.
OMI
$207.07M
ProQR Therapeutics N.V.
NASDAQ:PRQR
$197.55M
Aurora Cannabis Inc.
NASDAQ:ACB
$166.16M
CVRx, Inc.
NASDAQ:CVRX
$131.62M
Immutep Limited
NASDAQ:IMMP
$55.46M
Who manages LFCR?
Lifecore Biomedical, Inc. (LFCR) lists 8 active executives. The top listed executive is Paul Josephs, President, Chief Executive Officer & Director.
Are LFCR insiders buying or selling?
Recent insider activity shows net buying of $5.26M.
Explore More
Continue the stock analysis
Jump to another research area for this company.